CTIS.eu › Cities › France › Marseille
Marseille
France
1,485 total trials
664 recruiting
Filter these 1,485 trials by phase, condition, sponsor and more.
Open in Search →
2023-506185-31-00
10
2024-07-18
Idiopathic pulmonary fibrosis (IPF)
2023-505903-22-00
4
2024-07-02
Sepsis associated acute kidney injury
2023-506210-40-00
5
2024-06-28
Heart Failure due to Systemic Left Ventricular Systolic Dysfunction
2023-508377-82-00
10
2024-06-27
Hidradenitis Suppurativa (HS)
2023-505712-37-00
10
2024-06-06
The participants must have a histologically confirmed diagnosis of res
2023-505893-14-00
5
2024-06-04
Progressive Supranuclear Palsy
2022-502481-24-00
4
2024-05-23
Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)
2022-500918-25-00
5
2024-05-20
Marginal Zone Lymphoma
2023-506976-28-00
9
2024-05-16
Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
2023-503223-26-00
9
2024-05-07
Advanced Solid Tumors Harboring a KRASG12C Mutation
2023-505842-24-00
5
2024-05-07
Moderate to Severe Plaque Psoriasis
2023-507320-23-00
1
2024-04-26
Advanced Solid Tumors
2022-502899-23-00
5
2024-04-23
Hepatic Encephalopathy (OHE)
2023-504630-22-00
7
2024-04-19
Non-Small Cell Lung Cancer
2023-506038-65-00
4
2024-04-15
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE
METASTATIC BREAST CA
2023-503693-20-01
5
2024-04-10
Severe eosinophilic asthma
2023-506707-25-00
5
2024-04-09
Choroidal neovascularization secondary to pathologic myopia
2022-500823-61-00
7
2024-04-08
Advanced Solid Tumours
2023-505145-93-00
7
2024-03-21
Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma
2023-506660-13-00
6
2024-03-07
HIV-1 infection
2023-505396-71-00
4
2024-03-01
Early Alzheimer’s Disease with Biomarkers of Inflammation
2022-502467-38-00
4
2024-02-22
Non-small cell lung cancer (NSCLC)
2023-507321-42-00
1
2024-02-15
Myelodysplastic syndrome (MDS)
2023-505543-39-00
5
2024-02-12
Chronic Obstructive Pulmonary Disease (COPD)
Showing 1,249–1,272 of 1,485 trials